Cardiome/Astellas Schedule Kynapid Meeting With FDA
Meanwhile, Astellas yanks its Canadian new drug submission for the atrial fibrillation candidate to align its North American regulatory strategy.
Meanwhile, Astellas yanks its Canadian new drug submission for the atrial fibrillation candidate to align its North American regulatory strategy.